MHP-133, a drug with multiple CNS targets

Potential for neuroprotection and enhanced cognition

Jerry J. Buccafusco, James C. Powers, Maria A. Hernandez, Mark A. Prendergast, Alvin V Terry, Ramamohana R. Jonnala

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

MHP-133 is one of a novel series of compounds designed to target multiple brain substrates expected to have synergistic actions in the treatment of cognitive and neurodegenerative disorders such as Alzheimer's disease. The strategy was to develop compounds with multiple targets relevant for enhancing cognition and memory, but avoiding the serious side effects attributed to high potency cholinergic agonists. MHP-133 was shown to interact with subtypes of cholinergic, serotonergic, and imidazoline receptors and to weakly inhibit acetylcholinesterase activity. In vitro, the drug enhanced nerve growth factor (TrkA) receptor expression; it prevented excitotoxicity in a hippocampal slice preparation; and increased the secretion of soluble (non-toxic) amyloid precursor protein. MHP-133 also enhanced cognitive performance by rats and by non-human primate in tasks designed to assess working memory. The results of this study are consistent with the potential use of MHP-133 in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)1224-1237
Number of pages14
JournalNeurochemical Research
Volume32
Issue number7
DOIs
StatePublished - Jan 1 2007

Fingerprint

Cognition
Neurodegenerative Diseases
Pharmaceutical Preparations
Alzheimer Disease
trkA Receptor
Imidazoline Receptors
Data storage equipment
Nerve Growth Factor Receptor
Cholinergic Agonists
Amyloid beta-Protein Precursor
Cholinergic Receptors
Nerve Growth Factor
Acetylcholinesterase
Short-Term Memory
Cholinergic Agents
Primates
Rats
Brain
MHP 133
Neuroprotection

Keywords

  • 5HT receptors
  • Cholinergic receptors
  • Cognition
  • Delayed matching-to-sample
  • Drug development
  • Neurodegeneration
  • Non-human primates

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Buccafusco, J. J., Powers, J. C., Hernandez, M. A., Prendergast, M. A., Terry, A. V., & Jonnala, R. R. (2007). MHP-133, a drug with multiple CNS targets: Potential for neuroprotection and enhanced cognition. Neurochemical Research, 32(7), 1224-1237. https://doi.org/10.1007/s11064-007-9294-0

MHP-133, a drug with multiple CNS targets : Potential for neuroprotection and enhanced cognition. / Buccafusco, Jerry J.; Powers, James C.; Hernandez, Maria A.; Prendergast, Mark A.; Terry, Alvin V; Jonnala, Ramamohana R.

In: Neurochemical Research, Vol. 32, No. 7, 01.01.2007, p. 1224-1237.

Research output: Contribution to journalArticle

Buccafusco, JJ, Powers, JC, Hernandez, MA, Prendergast, MA, Terry, AV & Jonnala, RR 2007, 'MHP-133, a drug with multiple CNS targets: Potential for neuroprotection and enhanced cognition', Neurochemical Research, vol. 32, no. 7, pp. 1224-1237. https://doi.org/10.1007/s11064-007-9294-0
Buccafusco, Jerry J. ; Powers, James C. ; Hernandez, Maria A. ; Prendergast, Mark A. ; Terry, Alvin V ; Jonnala, Ramamohana R. / MHP-133, a drug with multiple CNS targets : Potential for neuroprotection and enhanced cognition. In: Neurochemical Research. 2007 ; Vol. 32, No. 7. pp. 1224-1237.
@article{cac707b549be417081660bf326c28349,
title = "MHP-133, a drug with multiple CNS targets: Potential for neuroprotection and enhanced cognition",
abstract = "MHP-133 is one of a novel series of compounds designed to target multiple brain substrates expected to have synergistic actions in the treatment of cognitive and neurodegenerative disorders such as Alzheimer's disease. The strategy was to develop compounds with multiple targets relevant for enhancing cognition and memory, but avoiding the serious side effects attributed to high potency cholinergic agonists. MHP-133 was shown to interact with subtypes of cholinergic, serotonergic, and imidazoline receptors and to weakly inhibit acetylcholinesterase activity. In vitro, the drug enhanced nerve growth factor (TrkA) receptor expression; it prevented excitotoxicity in a hippocampal slice preparation; and increased the secretion of soluble (non-toxic) amyloid precursor protein. MHP-133 also enhanced cognitive performance by rats and by non-human primate in tasks designed to assess working memory. The results of this study are consistent with the potential use of MHP-133 in the treatment of neurodegenerative disorders such as Alzheimer's disease.",
keywords = "5HT receptors, Cholinergic receptors, Cognition, Delayed matching-to-sample, Drug development, Neurodegeneration, Non-human primates",
author = "Buccafusco, {Jerry J.} and Powers, {James C.} and Hernandez, {Maria A.} and Prendergast, {Mark A.} and Terry, {Alvin V} and Jonnala, {Ramamohana R.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1007/s11064-007-9294-0",
language = "English (US)",
volume = "32",
pages = "1224--1237",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - MHP-133, a drug with multiple CNS targets

T2 - Potential for neuroprotection and enhanced cognition

AU - Buccafusco, Jerry J.

AU - Powers, James C.

AU - Hernandez, Maria A.

AU - Prendergast, Mark A.

AU - Terry, Alvin V

AU - Jonnala, Ramamohana R.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - MHP-133 is one of a novel series of compounds designed to target multiple brain substrates expected to have synergistic actions in the treatment of cognitive and neurodegenerative disorders such as Alzheimer's disease. The strategy was to develop compounds with multiple targets relevant for enhancing cognition and memory, but avoiding the serious side effects attributed to high potency cholinergic agonists. MHP-133 was shown to interact with subtypes of cholinergic, serotonergic, and imidazoline receptors and to weakly inhibit acetylcholinesterase activity. In vitro, the drug enhanced nerve growth factor (TrkA) receptor expression; it prevented excitotoxicity in a hippocampal slice preparation; and increased the secretion of soluble (non-toxic) amyloid precursor protein. MHP-133 also enhanced cognitive performance by rats and by non-human primate in tasks designed to assess working memory. The results of this study are consistent with the potential use of MHP-133 in the treatment of neurodegenerative disorders such as Alzheimer's disease.

AB - MHP-133 is one of a novel series of compounds designed to target multiple brain substrates expected to have synergistic actions in the treatment of cognitive and neurodegenerative disorders such as Alzheimer's disease. The strategy was to develop compounds with multiple targets relevant for enhancing cognition and memory, but avoiding the serious side effects attributed to high potency cholinergic agonists. MHP-133 was shown to interact with subtypes of cholinergic, serotonergic, and imidazoline receptors and to weakly inhibit acetylcholinesterase activity. In vitro, the drug enhanced nerve growth factor (TrkA) receptor expression; it prevented excitotoxicity in a hippocampal slice preparation; and increased the secretion of soluble (non-toxic) amyloid precursor protein. MHP-133 also enhanced cognitive performance by rats and by non-human primate in tasks designed to assess working memory. The results of this study are consistent with the potential use of MHP-133 in the treatment of neurodegenerative disorders such as Alzheimer's disease.

KW - 5HT receptors

KW - Cholinergic receptors

KW - Cognition

KW - Delayed matching-to-sample

KW - Drug development

KW - Neurodegeneration

KW - Non-human primates

UR - http://www.scopus.com/inward/record.url?scp=34249299108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249299108&partnerID=8YFLogxK

U2 - 10.1007/s11064-007-9294-0

DO - 10.1007/s11064-007-9294-0

M3 - Article

VL - 32

SP - 1224

EP - 1237

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 7

ER -